News: AHZ Admedus Says Cardiocel 3D And Vascucel Receives European Regulatory Approval, page-102

Sentiment is a function of performance. Not the other way around!

Wayne isn't bothering to talk up the company because no one would listen to him. Why would they given the colossal list of actions not following the talk? It's wasted breath now.

And I think most here do talk about the fundamentals, and it's a two sided coin. On the one hand AHZ have some apparently great IP with novel uses that should shock the industry. On the other hand there has been very little take up of this better product and revenue growth is being outstripped by expenses. While the CE approval is good, it son't address the companies immediate issues, which is perhaps why the ASX thought it worthy of a non-price sensitive rating (although I disagree, I think the the ASX have proved to be pretty useless and inconsistent and that it should be price sensitive)